Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

Summary

This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States. All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).

Timeline

Start

2021-12-06

Primary completion

2025-05

Completion

2025-10

Drugs

Indications